Botox Injection for CNS/ Neuromusc Dis: 62.4% of denials overturned
In 335 California IMR decisions from 2001 to 2025, reviewers overturned 209 (62.4%). In the last five years: 83.0% of 47. 116 were medical-necessity disputes, 219 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 9 | 88.9% |
| 2022 | 7 | 85.7% |
| 2023 | 4 | 25.0% |
| 2024 | 9 | 77.8% |
| 2025 | 18 | 94.4% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 121 | 81.0% | 62.4% |
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 96 | 65.6% | 62.4% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 66 | 48.5% | 62.4% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 46 | 69.6% | 62.4% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 39 | 5.1% | 62.4% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 36 | 80.6% | 62.4% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 26 | 61.5% | 62.4% |
| Urgent or emergencyThe findings mention urgency. | 6 | 100.0% | 62.4% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 4 | 50.0% | 62.4% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for Botox injections (onabotulinumtoxinA). Botox is U.S. Food and Drug Administration (FDA)-approved for management of primary axillary hyperhidrosis that is inadequately managed with topical agents. While the recommended dose is 100 units every three months, the treatment must be individualized. The patient has a history of axillary hyperhidrosis …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Botox injections. The patient in this case has been diagnosed with chronic migraines, has tried and failed other treatments and has experienced significant past symptom relief with Botox. Botox is a U.S. Food and Drug Administration (FDA)-approved medication with known efficacy and …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Xeomin. Xeomin is a safe, U.S. Food and Drug Administration (FDA)-approved treatment for cervical dystonia. Studies have demonstrated its efficacy in the treatment of dystonia. Studies show that Xeomin injected at shorter intervals was beneficial for patients. In this case, the patient …”
And one the reviewer upheld
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Botox injections.The records indicate that this patient has a history of headaches, jaw pain, and TMJ-related symptoms with a diagnosis of oromandibular dystonia and sleep-related bruxism. The patient has undergone treatment with heat, acupuncture, and chiropractic care, muscle relaxers, NSAIDs, and a mouth guard. The patient reported …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Botox Injection denials for CNS/ Neuromusc Dis overturned?
In 335 California IMR decisions from 2001 to 2025, reviewers overturned 209 (62.4%). In the last five years: 83.0% of 47. 116 were medical-necessity disputes, 219 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.